Literature DB >> 17993771

Treatment of severe psychosis due to ectopic Cushing's syndrome.

Y M Bilgin1, H E van der Wiel, H R Fischer, W W De Herder.   

Abstract

Severe psychosis in patients with Cushing's syndrome is rare and generally difficult to treat. We report a 46-yr-old woman suffering from Cushing's syndrome caused by an inoperable ACTH-producing lung carcinoma. She was initially treated with chemotherapy and radiotherapy. Six months later she presented with severe psychosis. Laboratory findings revealed a severe hypokalemia and metabolic alkalosis, which was caused by extremely high serum ACTH (788 ng/l) and cortisol (4.2 micromol/l). She was unresponsive to treatment with conventional antipsychotic drugs; she was therefore sedated and intubated. Treatment was started i.v. with etomidate, which blocks the cortisol synthesis, and orally by nasogastric tube with mifepristone, which competes with cortisol for binding to their receptors. To counteract adrenal insufficiency, she received corticosteroids. After 5 days there was a normalization of the ACTH, cortisol levels, and the metabolic disorders. After discontinuing etomidate she was extubated; there were no signs of psychosis observed. Computed tomography (CT) scan of the brain showed no metastasis, however CT scan of the abdomen showed liver metastasis and bilateral adrenal enlargement. Unfortunately, the clinical situation worsened and the patient died due to progression of the metastasis. This case report demonstrates the efficacy of a treatment of mifepristone with etomidate in a patient with an ectopic ACTH-producing Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17993771     DOI: 10.1007/BF03350817

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  12 in total

Review 1.  Mifepristone (RU 486): current knowledge and future prospects.

Authors:  J R Goldberg; M G Plescia; G D Anastasio
Journal:  Arch Fam Med       Date:  1998 May-Jun

2.  Effect of etomidate on hypercortisolism due to ectopic ACTH production.

Authors:  R Gärtner; M Albrecht; O A Müller
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

3.  Rapid reversal of psychotic depression using mifepristone.

Authors:  J K Belanoff; B H Flores; M Kalezhan; B Sund; A F Schatzberg
Journal:  J Clin Psychopharmacol       Date:  2001-10       Impact factor: 3.153

4.  The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism.

Authors:  L D Dorn; E S Burgess; T C Friedman; B Dubbert; P W Gold; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

5.  Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome.

Authors:  J Krakoff; C A Koch; K A Calis; R H Alexander; L K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

6.  Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

Authors:  H M Schulte; G Benker; D Reinwein; W G Sippell; B Allolio
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

7.  Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

Authors:  X Bertagna; C Bertagna; M H Laudat; J M Husson; F Girard; J P Luton
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

8.  Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486).

Authors:  A J van der Lely; K Foeken; R C van der Mast; S W Lamberts
Journal:  Ann Intern Med       Date:  1991-01-15       Impact factor: 25.391

9.  Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis.

Authors:  W M Drake; L A Perry; C J Hinds; D G Lowe; R H Reznek; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.

Authors:  L K Nieman; G P Chrousos; C Kellner; I M Spitz; B C Nisula; G B Cutler; G R Merriam; C W Bardin; D L Loriaux
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958

View more
  7 in total

Review 1.  Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

Authors:  Jens Heyn; Carolin Geiger; Christian L Hinske; Josef Briegel; Florian Weis
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 2.  Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management.

Authors:  Alicia Santos; Eugenia Resmini; Juan Carlos Pascual; Iris Crespo; Susan M Webb
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

Review 4.  Mifepristone: is there a place in the treatment of Cushing's disease?

Authors:  John D Carmichael; Maria Fleseriu
Journal:  Endocrine       Date:  2012-11-29       Impact factor: 3.633

Review 5.  Severe psychosis due to Cushing's syndrome in a patient with a carcinoid tumour in the lung: a case report and review of the current management.

Authors:  Mohamad Baba; Debamalya Ray
Journal:  World J Surg Oncol       Date:  2015-04-30       Impact factor: 2.754

6.  A case of madness resulting in a fortunate outcome; case report of a psychotic break as a result of cortisol secreting thymic neuroendocrine thymic tumor.

Authors:  Jibran Durrani; Faizan Malik; Naveed Ali; Syed Imran Mustafa Jafri; Mohsin Hamid
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-02-06

Review 7.  ACTH-producing thymic neuroendocrine tumor initially presenting as psychosis: A case report and literature review.

Authors:  Taiki Okumura; Shohei Takayama; Shin-Ichi Nishio; Takahiro Miyakoshi; Takuro Noguchi; Takashi Kobayashi; Toshirou Fukushima; Nodoka Sekiguchi; Toshiaki Otsuki; Mitsuhisa Komatsu; Tomonobu Koizumi
Journal:  Thorac Cancer       Date:  2019-06-11       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.